Is Jazz Pharmaceuticals Plc overvalued or undervalued?

As of 7 May 2025, the valuation grade for Jazz Pharmaceuticals Plc has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, with a P/E ratio of 14, a PEG ratio of 0.68, and an EV to EBITDA ratio of 7.69, which are competitive compared to its peers.
In comparison, Alnylam Pharmaceuticals, Inc. has a P/E ratio of -827.79, while Royalty Pharma Plc shows a more attractive P/E of 10.83. This suggests that Jazz Pharmaceuticals is positioned well relative to its peers, particularly in terms of earnings potential. Despite recent underperformance against the S&P 500, with a year-to-date return of -13.31% compared to the index's 2.44%, the valuation metrics indicate that Jazz Pharmaceuticals offers a compelling investment opportunity at its current price of 106.76.